泼尼松早期治疗非重症COVID-19肺炎的随机对照试验方案摘要
PREDCOVID试验是一项实用、非盲、随机、两臂平行试验,旨在评估早期泼尼松治疗能否减缓非重症COVID-19肺炎的进展。计划入组184例需氧疗但未机械通气的患者,主要复合终点为28天内入住ICU、需有创机械通气或全因死亡。
要点
- 早期泼尼松方案为第1-4天40mg,第5-8天20mg。
- 主要终点为28天内ICU入住、有创机械通气或全因死亡的复合终点。
- 计划入组184例,每组92例,1:1随机分组。
核心结论
- 该方案旨在评估早期泼尼松治疗能否降低非重症COVID-19肺炎的疾病进展风险。
研究设计与样本
- 实用、非盲、随机、两臂平行试验,计划入组184例,每组92例。
- 纳入18至90岁、RT-PCR确诊COVID-19肺炎、需氧疗但未机械通气的患者。
- 随机采用置换区组法,计算机生成随机数,1:1分配,统计师设盲。
关键数值与推荐
- 主要复合终点为第28天入住ICU、需有创机械通气或全因死亡。
- 次要终点包括呼吸恶化时间、需机械通气患者比例及机械通气天数。
- 重点观察需胰岛素治疗的血糖恶化、谵妄、医院感染及3-4级不良事件累积发生率。
临床怎么用
- 为临床医生提供早期糖皮质激素用于非重症COVID-19肺炎的疗效与安全性证据。
局限性
- 试验为非盲设计,患者和照料者均知晓分组。
- 单中心研究,样本量有限(共184例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the efficacy of early treatment with prednisone to decrease the progression of COVID-19 pneumonia. TRIAL DESIGN: This is a pragmatic, non-blinded, randomized, two arms, parallel trial. PARTICIPANTS: Patients between 18 and 90 years, with COVID-19 pneumonia, confirmed by RT PCR. The setting for the trial is the Hospital Santiago Oriente which is a secondary level hospital with an emergency room, intensive care, and all basic specialties of medicine. INCLUSION CRITERIA: 18 years or more COVID-19 confirmed by RT-PCR Oxygen requirements up to 35% by venturi mask or 5 liters per minute by nasal cannula (approximately FiO2 40%) Consent form signed Exclusion Criteria: Previous steroid use for more than 48 hours. Pregnancy Chronic respiratory failure Requirements of mechanical ventilation (invasive or no invasive) Chronic liver damage Child Pugh B or C Chronic kidney disease stage IV or V. Immunosuppressed Participation in another trial. INTERVENTION AND COMPARATOR: Experimental arm Prednisone 40 mg days 1 to 4. Then Prednisone 20 mg days 5 to 8. Usual care defined by the attending physician. Control arm No intervention. Usual care defined by the attending physician. MAIN OUTCOMES: Primary outcome Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation or All-cause Death by Day 28 Secondary outcomes (followed until day 28). Time to respiratory deterioration Incidence of patients requiring mechanical ventilation: Number of days on mechanical ventilation Special emphasis will be placed on observing the following serious adverse events Deterioration of the glycemic profile that requires the use of insulin Delirium Incidence of hospital infections (pneumonia, urinary tract infection, device associated infections) Cumulative incidence of grade 3 and 4 adverse events (AE). Interruption or temporary suspension of treatment for any reason RANDOMISATION: Randomisation in permuted block. Computer generated random numbers in an allocation rate of 1:1. Stata 14.0 was used. Allocated by the principal investigator (direct communication). BLINDING (MASKING): Patients not blinded. Caregivers not blinded. Participants not blinded. Statistician will not know the allocation. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): 92 patients in each arm. 184 total number of patients. TRIAL STATUS: Protocol version 2.0., approved October 2, 2020. Trial ongoing. Recruitment start: June 23, 2020. Anticipate finish recruiting: November 30, 2020. The protocol has been submitted before the last patient and last visit. The delay in sending to publication is responsibility of the authors. TRIAL REGISTRATION: Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia (PREDCOVID). Registration number NCT04451174 . Date of trial registration: June 26, 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
引用
- Salinas M, Andino P, Palma L, et al. Early use of corticosteroids in non-critical patients with COVID-19 pneumonia (PREDCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials. 2021. PMID: 33499887. doi:10.1186/s13063-021-05046-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。